Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
| ERICKSON AIR | EAC | 5.10% |
| ASSURED GUAR | AGO | 4.98% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Merit Medical Systems, Inc. (MMSI - Snapshot Report), a medical device company, recently obtained the clearance of the U.S. Food and Drug Administration (FDA) 510(k) to commercialize its Merit Laureate hydrophilic guide wire.
Following the FDA approval, it will be possible for Merit Medical to again market its Laureate hydrophilic guide wire in the U.S., which was discontinued earlier this year when the company received a warning letter from the FDA in February 2012. The FDA desired additional information about the modifications in the manufacturing process of the Laureate hydrophilic guide wire.
While the sale of Laureate hydrophilic guide wire was discontinued in the domestic market, the product continued to garner revenues in the international market, especially in China. Management believes that the offering provides a notable commercial opportunity in the domestic market as well.
Earlier, Merit Medical obtained the FDA 510(k) clearance for its Resolve Biliary Drainage Catheter and Concierge Guiding Catheter. Expectations from these newer offerings to bolster its top-line are high. Also worth mentioning in this context is management’s plans to extend its portfolio of hydrophilic wires by introducing additional varieties of the Laureate hydrophilic guide wire.
South Jordan, Utah-based Merit Medical provides disposable medical devices for cardiology, radiology, endoscopy and other interventional and diagnostic procedures. Founded in 1987, the company owns manufacturing facilities across U.S., Europe and China.
According to Merit Medical, its ability to develop and manufacture innovative products with proprietary technology will allow it to gain market share. Additionally, the company has significant international presence with China emerging as a major growth driver. It also plans to gain foothold in the BRIC nations and Balkan states.
Merit Medical strategizes to evolve as a provider of primary use products, apart from its accessory products. However, the company faces intense competition from large, diversified international players like Boston Scientific Corporation (BSX - Analyst Report), C.R. Bard (BCR - Analyst Report) as well as medium-size medical devices companies such as AngioDynamics (ANGO - Analyst Report) and ICU Medical (ICUI - Snapshot Report).
Merit Medical currently has a Zacks #2 Rank, which translates into a short-term Buy rating.
Get the full Analyst Report on BSX - FREE
Get the full Analyst Report on BCR - FREE
Get the full Analyst Report on ANGO - FREE
Get the full Snapshot Report on MMSI - FREE
Get the full Snapshot Report on ICUI - FREE